1. Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells
- Author
-
Hideyuki Yanai, Daisuke Yamamoto, Kazuhiko Koike, Ching-Yun Chang, Tatsuhiko Kodama, Sho Hangai, Masanobu Oshima, Sana Hibino, Takeshi Kawamura, Hiroko Oshima, Yousuke Nakai, Ryosuke Tateishi, Tadatsugu Taniguchi, Kyoji Moriya, and Yoshitaka Kimura
- Subjects
Male ,Chemokine CXCL1 ,medicine.medical_treatment ,Immunology ,Population ,Context (language use) ,Biology ,Mice ,Immune system ,Cancer immunotherapy ,Cell Line, Tumor ,Translationally-controlled tumor protein ,Biomarkers, Tumor ,Tumor Microenvironment ,medicine ,Alarmins ,Animals ,Humans ,Immunology and Allergy ,education ,Mice, Knockout ,Mice, Inbred BALB C ,education.field_of_study ,Tumor microenvironment ,Myeloid-Derived Suppressor Cells ,Tumor Protein, Translationally-Controlled 1 ,Immunotherapy ,Toll-Like Receptor 2 ,Mice, Inbred C57BL ,HEK293 Cells ,RAW 264.7 Cells ,Myeloid-derived Suppressor Cell ,Cancer research ,Female ,Colorectal Neoplasms - Abstract
One of most challenging issues in tumor immunology is a better understanding of the dynamics in the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TIME), as this would lead to the development of new cancer therapeutics. Here, we show that translationally controlled tumor protein (TCTP) released by dying tumor cells is an immunomodulator crucial to full-blown MDSC accumulation in the TIME. We provide evidence that extracellular TCTP mediates recruitment of the polymorphonuclear MDSC (PMN-MDSC) population in the TIME via activation of Toll-like receptor-2. As further proof of principle, we show that inhibition of TCTP suppresses PMN-MDSC accumulation and tumor growth. In human cancers, we find an elevation of TCTP and an inverse correlation of TCTP gene dosage with antitumor immune signatures and clinical prognosis. This study reveals the hitherto poorly understood mechanism of the MDSC dynamics in the TIME, offering a new rationale for cancer immunotherapy. Cell death in the context of cancer therapies is often associated with immunogenicity. Taniguchi and colleagues instead find that release of the cellular protein TCTP following cell death triggers an immunosuppressive pathway in the tumor microenvironment.
- Published
- 2021